<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01099514</url>
  </required_header>
  <id_info>
    <org_study_id>2009-02-026</org_study_id>
    <nct_id>NCT01099514</nct_id>
  </id_info>
  <brief_title>Study of Nilotinib in Metastatic Melanoma With KIT Aberrations</brief_title>
  <official_title>Phase II Study of Nilotinib in Metastatic Melanoma With KIT Aberrations</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Samsung Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Samsung Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Major response was observed to imatinib mesylate in KIT-mutated metastatic rectal melanoma
      (Hodi FS et al, J Clin Oncol 26:2046-2051, 2008). In the ASCO annual meeting in 2009ar, KIT
      mutations were reported to be present in 23% of acral and 15.2% of mucosal melanomas
      (Heinrich MC et al, J Clin Oncol 26:2008 abstr 9016). Nilotinib is a novel tyrosine kinase
      inhibitor (TKI) targeting KIT, PDGFR, and Bcr-Abl and inhibiting the proliferating of both
      imatinib-sensitive and imatinib-resistant cells in vitro. Phase I study of nilotinib alone
      and in combination with imatinib in patients with imatinib-resistant gastrointestinal stromal
      tumors (GIST) demonstrated significant activity (72% stable disease for nilotinib alone and
      56% for nilotinib/imatinib combination) (Blay JY et al, J Clin Oncol 26:2008, abstr 10553).

      Thus, we propose to conduct a phase II study of nilotinib in metastatic melanoma with KIT
      mutations.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2009</start_date>
  <completion_date type="Actual">June 2015</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>response rate</measure>
    <time_frame>1~2 year</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">33</enrollment>
  <condition>Metastatic Melanoma With KIT Aberration</condition>
  <arm_group>
    <arm_group_label>Nilotinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nilotinib 400 mg (2 capsules) PO BID q 28 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nilotinib</intervention_name>
    <description>D1~ Nilotinib 400 mg (2 capsules) PO BID q 28 days</description>
    <arm_group_label>Nilotinib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Histologically or cytologically proven melanoma with stage IV or unresectable stage
             III disease

          2. Documented KIT aberration

          3. Adequate organ function as defined by the following criteria:

               -  Serum aspartate transaminase (AST); serum glutamic oxaloacetic transaminase
                  (SGOT)) and serum alanine transaminase (ALT); serum glutamic pyruvic transaminase
                  (SGPT)) ≤ 2.5 x local laboratory upper limit of normal (ULN), or AST and ALT less
                  than or equal to 5 x ULN if liver function abnormalities are due to underlying
                  malignancy

               -  Total serum bilirubin ≤ 1.5 x ULN

               -  Absolute neutrophil count (ANC) ≥ 1500/µL

               -  Platelets ≥ 100,000/µL

               -  Hemoglobin ≥ 9.0 g/dL (may be transfused or erythropoietin treated)

               -  Serum calcium ≤ 12.0 mg/dL

               -  Serum creatinine ≤ 1.5 x ULN

          4. Patients with CNS metastasis must have stable neurologic function without evidence of
             CNS progression within 8 weeks

          5. May have previous adjuvant therapy with interferon, vaccines or therapy with IL-2,
             chemotherapy

          6. At least one measurable lesion by RECIST criteria

          7. ECOG PS 0-2

        Exclusion Criteria:

          1. Major surgery or radiation therapy within 4 weeks of starting the study treatment.

          2. History of or known carcinomatous meningitis, or evidence of symptomatic
             leptomeningeal disease on screening CT or MRI scan.

          3. Ongoing cardiac dysrhythmias of NCI CTCAE grade ≥ 2.

          4. QTc &gt; 470 msec on baseline EKG.

          5. Pregnancy or breastfeeding.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Samsung Cancer Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>December 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 6, 2010</study_first_submitted>
  <study_first_submitted_qc>April 6, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 7, 2010</study_first_posted>
  <last_update_submitted>December 28, 2015</last_update_submitted>
  <last_update_submitted_qc>December 28, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 29, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Samsung Medical Center</investigator_affiliation>
    <investigator_full_name>Jeeyun Lee</investigator_full_name>
    <investigator_title>Samsung medical center</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

